N-acelyltransferase 2 genotyping: An accurate and feasible approach for simultaneous detection of the most common NAT2 alleles

Clinical Chemistry

Volumn 50, Issue 7, 2004, Pages 1264-1266

  Brans, Richard ^a   Laizane, Danute ^a,c   Khan, Annika ^a   Blömeke, Brunhilde ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF TRIER   (Germany)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE 2; ISOENZYME; UNCLASSIFIED DRUG; ARYLAMINE ACETYLTRANSFERASE; NAT2 PROTEIN, HUMAN;

ACETYLATION; ALLELE; ANALYTIC METHOD; ARTICLE; DIAGNOSTIC KIT; DNA POLYMORPHISM; DRUG METABOLISM; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MEDICAL INSTRUMENTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; FEASIBILITY STUDY; GENETIC POLYMORPHISM; GENETICS; METHODOLOGY; MUTATION;

ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; FEASIBILITY STUDIES; GENOTYPE; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 3042662702     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.027748     Document Type: Article

References (13)

1. Price Evans MK, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960;2:485-91.
2. Timbrell JA, Harland SJ, Facchini V. Polymorphic acetylation of hydralazine. Clin Pharmacol Ther 1980;28:350-5.
3. Reidenberg MM, Drayer DE, Levy M, Warner H. Polymorphic acetylation procainamide in man. Clin Pharmacol Ther 1975;17:722-30.
4. Clark DW. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 1985;29:342-75.
5. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-96.
6. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
7. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 2003;4:1-4.
8. Cascorbi I, Brockmoller J, Bauer S, Reum T, Roots I. NAT2*12A (803A→G) codes for rapid arylamine n-acetylation in humans. Pharmacogenetics 1996;6:257-9.
9. Biomeke B, Sieben S, Spotter D, Landt O, Merk HF. Identification of N-acetyltransferase 2 genotypes by continuous monitoring of fluorogenic hybridization probes. Anal Biochem 1999;275:93-7.
10. Dandara C, Masimirembwa CM, Magimba A, Kaaya S, Sayi J, Sommers de K, et al. Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A. Pharmacogenetics 2003;13:55-8.
11. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
12. Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, Weber WW. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 2000;28:1425-32.
13. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003;348:553-6.